Skip to content
Screener

Opus Genetics IRD Debt-to-equity

Debt-to-equity at other companies

AbbVie logo
AbbVieABBV
46.6×+38.6×
MeiraGTx Holdings plc logo
MeiraGTx Holdings plcMGTX
27.2×+26.1×
Regenxbio logo
RegenxbioRGNX
1×+0.6×
4D Molecular Therapeutics logo
4D Molecular TherapeuticsFDMT
0×0.0×
Opko Health logo
Opko HealthOPK
0×0.0×
uniQure logo
uniQureQURE
0.2×—

Other financials

Income statement

See full
Revenue$2.2M-50.6%
Operating income-$14.4M-44.7%
Net income-$65.5M-700%
EPS (diluted)-$0.75-213%

Balance sheet

See full
Cash & equivalents$60.0M+43.5%
Total debt$1.2M—
Total equity-$45.8M-1,004%
Total assets$66.8M+38.7%

Cash flow

See full
Operating cash flow-$12.7M-41.5%

Valuation

See full
Market cap$304.5M+381%
Enterprise value$245.74M+672%
P/S25.4×+21.3×

Profitability

See full
Operating margin-359.1%-68.9pp
Net margin-892.4%-12,322pp

Returns & leverage

See full
Return on equity-449.4%-2,573pp
Current ratio7.1×+5.2×

Where this comes from

Calculated from Opus Genetics’s reported figures.

total debt/total stockholders equity=0.1×

Based on the most recent quarter.

The source filing: Opus Genetics’s 10-Q, filed May 12, 2026. Open the filing →

Filed
May 12, 2026, 4:03 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001628280-26-034084

FAQ

What is Opus Genetics's debt-to-equity?
Opus Genetics (IRD) reported debt-to-equity of 0.1× in Q4 2025.
What does debt-to-equity mean?
Total debt (including capitalized leases and financing obligations) divided by shareholders' equity at the quarter end. Measures how much the company is financed by debt relative to equity.

Ask your AI about Opus Genetics's debt-to-equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude